Scarica l'app Stockscreener
6.66
2.92%
-0.20
Dopo l'orario di chiusura:
6.30
-0.36
-5.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results - Bitget
Aligos Therapeutics (ALGS) Reports Lower Q4 Revenue and Advances Key Studies - GuruFocus
ALIGOS THERAPEUTICS ($ALGS) Releases Q4 2025 Earnings - Quiver Quantitative
Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing - TradingView
Aligos Therapeutics Earnings Report: Q4 Overview - Benzinga
Aligos Therapeutics Q4 net loss narrows - TradingView
Growth Report: Will Aligos Therapeutics Inc benefit from current market trendsM&A Rumor & High Win Rate Trade Alerts - baoquankhu1.vn
Big loss reduction as Aligos (NASDAQ: ALGS) advances HBV and obesity pipeline - Stock Titan
ALGS SEC FilingsAligos Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
A Peek at Aligos Therapeutics's Future Earnings - Benzinga
ALGS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on Monday - Defense World
9 Pharma Trends To Watch In 2026 - Pharmaceutical Online
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play - TipRanks
Aligos Therapeutics Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 - Caledonian Record
Aligos Therapeutics (ALGS) Reports Encouraging Findings at CROI 2026 - GuruFocus
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) - The Manila Times
Aligos Therapeutics, Inc. Reports Positive Data from CROI Presentations on Pevifoscorvir Sodium and ALG-097558 - Quiver Quantitative
Aligos data hint at high hepatitis B viral suppression, new COVID protease drug - Stock Titan
Risk On: What is ILMNs P E ratio telling usJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Will Aligos Therapeutics Inc outperform its industry peersWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Moving Averages: What analysts say about Aligos Therapeutics Inc stockMarket Growth Review & Fast Momentum Entry Tips - baoquankhu1.vn
Can Aligos Therapeutics Inc. continue delivering strong returnsRecession Risk & Trade Opportunity Analysis Reports - mfd.ru
Trading the Move, Not the Narrative: (ALGS) Edition - Stock Traders Daily
Officer stock option holdings disclosed at Aligos Therapeutics (ALGS) - Stock Titan
Woodline Partners reports 5.4% Aligos (ALGS) stake in amended 13G - Stock Titan
Will Aligos Therapeutics Inc. benefit from current market trends2025 Stock Rankings & AI Forecast Swing Trade Picks - mfd.ru
What are the future prospects of DWSNMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Aligos Therapeutics Inc. weather a recessionMarket Weekly Review & Daily Profit Maximizing Trade Tips - mfd.ru
ALGS Should I Buy - Intellectia AI
Rally Mode: What analysts say about Aligos Therapeutics Inc stockMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Aligos Therapeutics: Pipeline Progress and Financial Runway Under the Microscope - AD HOC NEWS
(ALGS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aligos Therapeutics Appoints New Principal Accounting Officer - The Globe and Mail
Aligos Therapeutics Grants Non-Qualified Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Aligos gives new hires options on 81,100 shares - Stock Titan
Aligos Therapeutics secures $105 million in private placement - MSN
Price-Driven Insight from (ALGS) for Rule-Based Strategy - Stock Traders Daily
Aligos Therapeutics edges higher after update on Phase 2 HBV trial - MSN
Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress - Investing.com
Aligos reports progress on Phase 2 hepatitis B drug study By Investing.com - Investing.com Australia
Aligos Therapeutics stock rises on Phase 2 HBV study progress By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock rises on Phase 2 HBV study progress - Investing.com
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - Investing News Network
ALGS Executive Vice President and Chief Medical Officer Resigns - GuruFocus
Aligos Therapeutics (ALGS) Updates on Phase 2 Study for Hepatitis B Treatment - GuruFocus
Aligos reports progress on Phase 2 hepatitis B drug study - Investing.com
Aligos Therapeutics provides phase 2 B-SUPREME study progress updates - marketscreener.com
Aligos Therapeutics, Inc. Provides Phase 2 B-Superme Study Progress Updates - marketscreener.com
ALGS: Piper Sandler to Host Virtual Meeting on January 22 - GuruFocus
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):